[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100654197":3},{"organization":4,"outcomesModule":7,"designInfo":21,"detailedDescription":11,"studyPopulation":11,"armGroups":30,"interventions":43,"overallOfficials":51,"centralContacts":56,"locations":62,"responsibleParty":81,"collaborators":11,"id":83,"slug":84,"hasResults":85,"nctId":86,"briefTitle":87,"officialTitle":87,"acronym":11,"eligibilityCriteria":88,"healthyVolunteers":89,"sex":90,"minAge":91,"maxAge":92,"enrollmentInfo":93,"targetDuration":11,"studyType":96,"phases":97,"briefSummary":99,"conditions":100,"keywords":11,"overallStatus":65,"whyStopped":11,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":111},{"fullName":5,"class":6},"Hemab ApS","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":11},[9],{"measure":10,"description":11,"timeFrame":12},"Number of participants with treatment emergent adverse events (TEAEs)",null,"From Day 1 up to 42 days after a single dose of study drug on Day 1",[14,17,19],{"measure":15,"description":11,"timeFrame":16},"Plasma concentration of HMB-003","From 0 hours (pre-dose) to 42 days after a single dose on Day 1",{"measure":18,"description":11,"timeFrame":16},"Urine concentration of HMB-003",{"measure":20,"description":11,"timeFrame":16},"Pharmacodynamic parameter: Clot lysis",{"allocation":22,"interventionModel":23,"interventionModelDescription":11,"primaryPurpose":24,"observationalModel":11,"timePerspective":11,"maskingInfo":25},"RANDOMIZED","PARALLEL","TREATMENT",{"masking":26,"maskingDescription":11,"whoMasked":27},"DOUBLE",[28,29],"PARTICIPANT","INVESTIGATOR",[31,37],{"label":32,"type":33,"description":34,"interventionNames":35},"HMB-003","EXPERIMENTAL","Participants will be administered a single dose of HMB-003 at an escalating dose level according to the assigned cohort.",[36],"Drug: HMB-003",{"label":38,"type":39,"description":40,"interventionNames":41},"Placebo","PLACEBO_COMPARATOR","Participants will be administered a single dose",[42],"Drug: Placebo",[44,48],{"type":45,"name":32,"description":46,"armGroupLabels":47,"otherNames":11},"DRUG","HMB-003 will be administered subcutaneously as a single dose",[32],{"type":45,"name":38,"description":49,"armGroupLabels":50,"otherNames":11},"Placebo will be administered subcutaneously as a single dose of placebo.",[38],[52],{"name":53,"affiliation":54,"role":55},"Medical Director","Hemab","STUDY_DIRECTOR",[57],{"name":58,"role":59,"phone":60,"phoneExt":11,"email":61},"Clinical Trials","CONTACT","001 888 493 8148","clinicaltrials@hemab.com",[63],{"facility":64,"status":65,"city":66,"state":67,"zip":68,"country":69,"countryCode":70,"cosmosGeoPoint":71,"geoPoint":76,"contacts":77},"Worldwide Clinical Trials","RECRUITING","San Antonio","Texas","78217","United States","US",{"type":72,"coordinates":73},"Point",[74,75],-98.49363,29.42412,{"lat":75,"lon":74},[78],{"name":64,"role":59,"phone":79,"phoneExt":11,"email":80},"210-635-1515","participate@worldwide.com",{"type":82,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100654197","phase-1-a-first-in-human-study-to-assess-the-safety-pharmacokinetics-and-pharmacodynamics-of-hmb-003-in-healthy-volunteers-100654197",false,"NCT07798505","A First-in-Human Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of HMB-003 in Healthy Volunteers","Inclusion Criteria:\n\n* Participant is aged 18 to 50 years, inclusive, at the time of signing informed consent.\n* Overall healthy as determined by medical evaluation including physical examination, vital signs, laboratory tests, and ECG.\n\nExclusion Criteria:\n\n* Participant has a history of clinically significant hypersensitivity to any excipients of the study drug\n* Participant is pregnant, breastfeeding, or \\\u003C6 weeks postpartum.\n* Participant has received investigational drug or device in another clinical study within 30 days or 5 half-lives, whichever is longer, before dosing.",true,"ALL","18 Years","50 Years",{"count":94,"type":95},40,"ESTIMATED","INTERVENTIONAL",[98],"PHASE1","The purposes of this clinical study are\n\n1. To see how the new drug (HMB-003) under study is tolerated in healthy volunteers, and if there are any important side effects.\n2. To measure the amount of HMB-003 in the body after injection.",[101],"Healthy Adult Participants","2026-09-09",{"date":104,"type":105},"2026-09-10","ACTUAL",{"date":107,"type":95},"2026-08-17",{"date":109,"type":95},"2027-04-30",{"name":5,"class":6},1]